Fast Five Quiz: Direct Oral Anticoagulant Therapy for Atrial Fibrillation

Sandeep K. Goyal, MD


April 02, 2020

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it is estimated to affect 33.5 million people worldwide. Patients with AF are at an increased risk for stroke, which is a risk that increases in the presence of other risk factors. Fortunately, anticoagulation therapy can reduce the risk for stroke in patients with AF. Recently, the use of older anticoagulant agents has been minimized due to their narrow therapeutic window and requirement for frequent monitoring and dose adjustments. Because of these limitations, direct oral anticoagulant (DOAC) agents are a more favorable option for most patients, showing slightly improved efficacy at lowering the risk of stroke, major bleeding, and mortality in patients with AF without the need for diet changes or constant monitoring.

How much do you know about the use of DOAC agents as anticoagulation therapy in patients with AF? Take our short quiz to find out.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.